| abstract |
The present invention relates to the field of biotechnology, and more particularly to Zika/dengue vaccines and their applications. In the present invention, based on crystal structure analysis and other structural and functional analysis, epitope information of the main antibody causing the ADE effect was obtained. The antigen according to an embodiment of the present invention is an antigen in which a mutation is introduced into the E protein FL fusion region of Zika virus or Dengue virus, and none of the antigens having the mutation can bind to an ADE-inducing antibody (FLE antibody). ; The vaccine obtained based on the antigen provided by the present invention can avoid the production of antibodies by induction of the FL epitope after immunization, thereby reducing or eliminating the ADE effect. |